NCT03255174 - The EVARREST® Pediatric Mild or Moderate Liver and Soft Tissue Bleeding Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 20, 2018

Primary Completion Date

January 22, 2025

Study Completion Date

February 14, 2025

Conditions

Controlling Mild to Moderate Bleeding During Surgery

Interventions

BIOLOGICAL

EVARREST® Fibrin Sealant Patch

EVARREST Fibrin Sealant Patch is a sterile, bio-absorbable combination product consisting of two constituent parts- a flexible matrix and a coating of biological components (human plasma-derived fibrinogen and thrombin) embedded in a flexible composite patch component.

Trial Locations (5)

10029

icahn School of Medicine at Mt Sinai, New York

35222

University of Alabama Hospital, Birmingham

B4 6NH

Birmingham Chrildren's Hospital, Birmingham

NE1 4LP

Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne

SO16 6YD

Southampton University Hospital, Southampton

All Listed Sponsors

lead

Ethicon, Inc.

INDUSTRY